Anti-FGFR3 antibody,Abcam,AB10651
Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (MW 17-38 kD) that are potent physiological regulators of growth and differentiation for a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, and in hematopoiesis as well as in tissue remodelling and maintenance. They have also been implicated in pathological conditions such as tumorigenesis and metastasis. The FGF family consists of at least seventeen members designated FGF1 through FGF17. To date, four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2) and by alternative splicing have been reported. Soluble, secreted or possibly cleaved forms of FGFR-1 and FGFR-2 have also been found in body fluids or were artificially constructed. An example is a soluble FGF-binding protein containing the extracellular region of FGFR3 and the secreted form of placental alkaline phosphatase (FRAP3). FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110-150 kD proteins consiting of an extracellular domain, a single transmembrane region and a cytoplasmic split tyrosine kinase domain, which is activated following ligand binding and receptor dimerization. The extracellular, ligand binding, region is constructed with either two (beta type) or typically three (alpha-type) immunoglobulin (Ig)-like domains, and an eight amino acid ‘acidic box’. The ligand binding site of all FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind several of the FGFs with a similar affinity. Also, one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGFs binding to cellular FGFRs depend on, or is markedly facilitated by the low-affinity interaction of FGFs with the polysaccharide component of cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signalling molecules leads to DNA synthesis or differentiation. The signalling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. FGFR3 is widely expressed in many fetal and adult human and animal tissues. The FGFR3 expression profile largely correlates with its tissue specific expression at the mRNA level.
Host
Rabbit
Reactivity
Human
Application
WB, IHC-P
Platform ID
BAB302499082

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. See full target information FGFR3
Category Paths
- Products>Primary Antibodies>Polyclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
Please provide the required information below so that we can quickly source your products.
